In a parallel project, we are characterizing the impact of dyslipidemia in the chemoresistance acquisition; therefore, we are developing this project, “Low-density lipoproteins (LDL) promote lapatinib chemoresistance through metabolism dysregulation of drug and lipid targets in HER2+ breast cancer” (in process). This evidence concerns the gene ERBB2 and breast carcinoma.